Analysts expect Allena Pharmaceuticals, Inc. (NASDAQ:ALNA – Get Rating) to post ($0.20) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Allena Pharmaceuticals’ earnings. Allena Pharmaceuticals reported earnings of ($0.21) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 4.8%. The company is expected to issue its next earnings results on Monday, January 1st.
Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Allena Pharmaceuticals.
Allena Pharmaceuticals (NASDAQ:ALNA – Get Rating) last posted its earnings results on Thursday, March 31st. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05.
NASDAQ ALNA traded up $0.01 during trading hours on Thursday, hitting $0.22. 22,223 shares of the company’s stock were exchanged, compared to its average volume of 2,305,657. The stock has a 50-day simple moving average of $0.36 and a 200 day simple moving average of $0.57. Allena Pharmaceuticals has a 1-year low of $0.21 and a 1-year high of $1.45. The firm has a market cap of $18.33 million, a price-to-earnings ratio of -0.26 and a beta of 1.92.
A number of institutional investors have recently modified their holdings of the stock. Altium Capital Management LP bought a new stake in Allena Pharmaceuticals during the third quarter worth $963,000. Morgan Stanley raised its stake in shares of Allena Pharmaceuticals by 63.9% in the second quarter. Morgan Stanley now owns 1,045,481 shares of the company’s stock valued at $1,359,000 after buying an additional 407,599 shares during the period. Geode Capital Management LLC raised its stake in shares of Allena Pharmaceuticals by 15.8% in the third quarter. Geode Capital Management LLC now owns 330,599 shares of the company’s stock valued at $298,000 after buying an additional 45,032 shares during the period. Millennium Management LLC raised its stake in shares of Allena Pharmaceuticals by 75.5% in the second quarter. Millennium Management LLC now owns 187,431 shares of the company’s stock valued at $244,000 after buying an additional 80,625 shares during the period. Finally, Kestra Advisory Services LLC raised its stake in shares of Allena Pharmaceuticals by 53.8% in the fourth quarter. Kestra Advisory Services LLC now owns 161,500 shares of the company’s stock valued at $96,000 after buying an additional 56,500 shares during the period. Institutional investors and hedge funds own 24.20% of the company’s stock.
About Allena Pharmaceuticals (Get Rating)
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
- Get a free copy of the StockNews.com research report on Allena Pharmaceuticals (ALNA)
- Institutional Buying Puts A Bottom In Manpower Group Inc
- Workhorse Johnson & Johnson Plows New All-Time Highs
- Fastenal Stock is Ready to Sprint Higher
- J.B. Hunt Transportation Services Fires On All Cylinders
- 3 No-Brainer Stocks to Buy with $1000
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.